Top View
- Molecular Imaging in Cancer Drug Development
- Vandetanib (Caprelsa) Reference Number: CP.PHAR.80 Effective Date: 10/11 Coding Implications Last Review Date: 03/17 Revision Log
- Vandetanib and Risk of QT Prolongation, Torsades De Pointes and Sudden Death
- Bladder Cancer
- Oncology Oral, Other Therapeutic Class Review
- ZEPHYR: Failure of a “Spring Wind” in Lung Cancer
- PDL)/Non-Preferred Drug List (NPDL
- Qtc Interval Prolongation with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
- Vandetanib Photoinduced Cutaneous Toxicities
- Cardiovascular Health During and After Cancer Therapy
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Selumetinib with Radioactive Iodine Therapy for Differentiated Thyroid Cancer – First Line
- Ram-Systemic-Therapy
- Vandetanib and Lenvatinib for the Treatment of Thyroid Cancers
- Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Therapeutic Drug Monitoring of 9 New Anticancer Agents by High-Performance Liquid Chromatography-Tandem Mass Spectrometry V
- Combining Targeted Therapeutics in the Era of Precision Medicine
- Improvement of Overall Survival Using Tkis As Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience
- PRESCRIBING INFORMATION • QT Interval Prolongation: Monitor Patients Who Are at Significant Risk of Developing Qtc Prolongation
- Oncology Therapy for the Generalist
- Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer
- Comparative Analysis of Drug Response and Gene Profiling Of
- CAPRELSA, INN-Vandetanib
- Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
- Molecular Alterations in Thyroid Cancer: from Bench to Clinical Practice
- Receptor Tyrosine Kinases (Rtks) in Breast Cancer
- Cabozantinib and Vandetanib for Unresectable Locally Advanced Or Metastatic Medullary Thyroid Cancer: a Systematic Review and Economic Model
- Response and Toxicity of Small-Molecule Tyrosine Kinase Inhibitors in Patients with Thyroid Carcinoma: a Systematic Review and Meta-Analysis
- 022405Orig1s000
- Cabozantinib and Vandetanib for Treating Medullary Thyroid Cancer
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Rare Complications of Multikinase Inhibitor Treatment
- Combination of Vandetanib, Radiotherapy, and Irinotecan in the Lovo Human Colorectal Cancer Xenograft Model
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Caprelsa (Vandetanib)
- Non-Preferred Drug List (NPDL)
- A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-- Deficient Gastrointestinal Stromal Tumor John Glod1, Fernanda I
- Pharmacologic Effects of RET Antibody Drug Conjugates Page 1
- Caprelsa, INN, Vandetanib
- Pazopanib: Drug Information
- Vandetanib (Caprelsa®) Abbreviated National Drug Monograph May 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- And Nilotinib-Induced Inhibition of the Cardiac Ikr Channel and Qtc Prolongation
- Brain Distribution of a Panel of EGFR Inhibitors Using Cassette-Dosing in Wild-Type and Abcb1/Abcg2 Deficient Mice
- Proliferation of Ewing Sarcoma Cell Lines Is Suppressed by the Receptor Tyrosine Kinase Inhibitors Gefitinib and Vandetanib Mattias K Andersson* and Pierre Åman
- Vandetanib for the Treatment of Medullary Thyroid Cancer
- Vandetanib Inhibits Both VEGFR-2 and EGFR Signalling at Clinically Relevant Drug Levels in Preclinical Models of Human Cancer
- Term Cardiovascular Effects of Vandetanib and Pazopanib in Normotensive Rats
- Vandetanib Is Effective in EGFR-Mutant Lung Cancer Cells with PTEN Deficiency
- Trastuzumab Emtansine > Printer-Friendly PDF
- HER2 BC State of the Art Landscape Report
- Thyroid Effects of Tyrosine Kinase Inhibitors
- Updated Insights on EGFR Signaling Pathways in Glioma